2015ANNUAL REPORT

The Modes of Action of Vaccine Adjuvants (S1)Organizers: Philippa C. Marrack, Steven Reed & Robert A. SederOctober 8–13, 2014 | Seattle, Washington | USACell Death Signaling in Cancer & the Immune System (S2)Organizers: Gustavo Amarante-Mendes, Douglas R. Green & Kim NewtonOctober 28–November 2, 2014 | Guarujá, São Paulo | Brazil Precision Genome Engineering & Synthetic Biology (A1)Organizers: Philip D. Gregory, Jennifer A. Doudna & Ron WeissJanuary 11–16, 2015 | Big Sky, Montana | USAViral Immunity (A2) Organizers: Jonathan W. Yewdell, Donna L. Farber, Nicole Baumgarth & Jack R. Bennink January 11–16, 2015 | Breckenridge, Colorado | USAThe Biological Code of Signaling – A Tribute to Tony Pawson (F1)Organizers: Tony Hunter & Rune LindingJanuary 11–16, 2015 | Steamboat Springs, Colorado | USAIntegrating Metabolism & Tumor Biology (J1)Organizers: Ralph J. DeBerardinis, Robert T. Abraham & Eyal Gottliebjoint with PI 3-Kinase Signaling Pathways in Disease (J2)Organizers: Lori Friedman, David A. Fruman & Phillip T. HawkinsJanuary 13–18, 2015 | Vancouver, British Columbia | CanadaImmunity to Veterinary Pathogens: Informing Vaccine Development (A3)Organizers: William T. Golde, Wendy C. Brown & Ivan MorrisonJanuary 20–25, 2015 | Keystone, Colorado | USAHost Response in Tuberculosis (J3)Organizers: JoAnne L. Flynn & Willem A. Hanekom joint with Granulomas in Infectious & Non-Infectious Diseases (J4)Organizers: Thomas A. Wynn, Paul Kaye & Vishva M. DixitJanuary 22–27, 2015 | Santa Fe, New Mexico | USAEpigenetics & Cancer (A4)Organizers: Tony Kouzarides & Kristian HelinJanuary 25–30, 2015 | Keystone, Colorado | USANeuroinflammation in Diseases of the Central Nervous System (A5)Organizers: Richard M. Ransohoff, Christopher K. Glass & V. Hugh PerryJanuary 25–30, 2015 | Taos, New Mexico | USAMitochondria, Metabolism & Heart Failure (J5)Organizers: Richard N. Kitsis, Gerald W. Dorn II & Rong Tianjoint with Diabetes & Metabolic Dysfunction (J6)Organizers: Jeffrey E. Pessin, Alan R. Saltiel & Deborah M. MuoioJanuary 27–Feb 1, 2015 | Santa Fe, New Mexico | USAAutoimmunity & Tolerance (B1)Organizers: Jane L. Grogan, Joanne L. Viney & Gerald T. NepomFebruary 3–8, 2015 | Keystone, Colorado | USAEndoderm Lineages in Development & Disease (B2)Organizers: Lori Sussel, Hans-Willem E. Snoeck, James M. Wells & Aaron M. ZornFebruary 8–13, 2015 | Keystone, Colorado | USAPlant Receptor Kinases: From Molecules to Environment (B3)Organizers: Cyril Zipfel & Steven C. HuberFebruary 8–13, 2015 | Taos, New Mexico | USATumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)Organizers: Elizabeth M. Jaffee & Axel X. Hoos joint with Antibodies as Drugs: Immunological Scaffolds as Therapeutics (J8)Organizers: Pablo Umaña, Mark X. Sliwkowski & Martin J. GlennieFebruary 8–13, 2015 | Banff, Alberta | CanadaSystems Biology of Lipid Metabolism (B4)Organizers: Matej Orešič, Antonio J. Vidal-Puig & Ana Maria CuervoFebruary 9–13, 2015 | Breckenridge, Colorado | USARNA Silencing in Plants (G1)Organizers: Robert Martienssen & Craig S. PikaardFebruary 17–22, 2015 | Keystone, Colorado | USANeuroepigenetics (B5)Organizers: Hongjun Song & Li-Huei TsaiFebruary 22–26, 2015 | Santa Fe, New Mexico | USAHematopoiesis (B6)Organizers: Timm Schroeder, Hanna K.A. Mikkola & Patricia ErnstFebruary 22–27, 2015 | Keystone, Colorado | USAGut Microbiota Modulation of Host Physiology: The Search for Mechanism (C1)Organizers: Fredrik Bäckhed, Ruth E. Ley & Yasmine BelkaidMarch 1–6, 2015 | Keystone, Colorado | USAHeart Disease & Regeneration: Insights from Development (X1)Organizers: Vincent M. Christoffels, James F. Martin & Deborah L. Yelonjoint with Cell Biology of the Heart: Beyond the Myocyte-Centric View (X2)Organizers: Peter Kohl, Robert G. Gourdie & Stefanie DimmelerMarch 1–6, 2015 | Copper Mountain, Colorado | USADNA Replication & Recombination (X3)Organizers: Simon J. Boulton, Karlene A. Cimprich & Stephen D. Belljoint with Genomic Instability & DNA Repair (X4)Organizers: Daniel Durocher, Jiri Lukas & Agata SmogorzewskaMarch 1–6, 2015 | Whistler, British Columbia | CanadaHybrid Methods in Structural Biology (C2)Organizers: Jens Meiler, Patrick Cramer & Ron A. MilliganMarch 4–8, 2015 | Tahoe City, California | USA

Biology of Sirtuins (C3)Organizers: Raul Mostoslavsky, Shin-ichiro Imai, Marcia C. Haigis & Eric M. VerdinMarch 8–12, 2015 | Santa Fe, New Mexico | USADendritic Cells & Macrophages Reunited (C4)Organizers: Jacques F. Banchereau & Siamon GordonMarch 8–13, 2015 | Montreal, Quebec | CanadaOptogenetics (C5)Organizers: Edward S. Boyden, Klaus M. Hahn & Chandra TuckerMarch 12–16, 2015 | Denver, Colorado | USACo-Infection: A Global Challenge for Disease Control (C6)Organizers: Rodrigo Corrêa-Oliveira, David Dunne & Andrea GrahamMarch 15–20, 2015 | Ouro Preto, Minas Gerais | BrazilLong Noncoding RNAs: From Evolution to Function (C7)Organizers: Leonard Lipovich, Jeannie T. Lee, John L. Rinn & James (Ben) BrownMarch 15–20, 2015 | Keystone, Colorado | USAPathways of Neurodevelopmental Disorders (C8)Organizers: Randi J. Hagerman, Mustafa Sahin & Paul J. HagermanMarch 16–20, 2015 | Tahoe City, California | USAHIV Vaccines (X5)Organizers: Giuseppe Pantaleo, Rafick P. Sekaly & Leonidas Stamatatosjoint with The Golden Anniversary of B Cell Discovery (X6) Organizers: Patrick C. Wilson, Michael P. Cancro & Anne DurandyMarch 22–27, 2015 | Banff, Alberta | CanadaObesity and the Metabolic Syndrome: Mitochondria & Energy Expenditure (X7)Organizers: Johan Auwerx, Eleftheria Maratos-Flier & Thomas Langerjoint with Liver Metabolism & Nonalcoholic Fatty Liver Disease (NAFLD) (X8)Organizers: Jay D. Horton, Douglas G. Mashek & Brian N. FinckMarch 22–27, 2015 | Whistler, British Columbia | CanadaTranscriptional & Epigenetic Influences on Stem Cell States (C9)Organizers: Thomas P. Zwaka, Rudolf Jaenisch & Joanna WysockaMarch 23–28, 2015 | Steamboat Springs, Colorado | USAGram-Negative Resistance (D1)Organizers: Robert E.W. Hancock & Eric D. BrownMarch 29–April 2, 2015 | Tahoe City, California | USAViruses & Human Cancer (D2)Organizers: Charles R.M. Bangham, Thomas F. Schulz & Paul M. LiebermanMarch 29–April 3, 2015 | Big Sky, Montana | USAT Cells: Regulation & Effector Function (D3)Organizers: Alexander Y. Rudensky, Dan R. Littman & Kristin A. HogquistMarch 29–April 3, 2015 | Snowbird, Utah | USADNA Methylation (Z1) Organizers: Alexander Meissner & Dirk Schübeler joint with Epigenomics (Z2)Organizers: Bing Ren & Daniel ZilbermanMarch 29–April 3, 2015 | Keystone, Colorado | USANeural Control of Metabolic Physiology & Diseases (D4)Organizers: Dongsheng Cai & Martin G. Myers, Jr.April 12–17, 2015 | Snowbird, Utah | USABeige and Brown Fat: Basic Biology & Novel Therapeutics (D5)Organizers: Bruce M. Spiegelman & Sven EnerbäckApril 17–22, 2015 | Snowbird, Utah | USAThe Crossroads of Lipid Metabolism & Diabetes (D6)Organizers: Russell A. DeBose-Boyd, Sudha Biddinger & Alan D. AttieApril 19–24, 2015 | Copenhagen | DenmarkInnate Immunity & Determinants of Microbial Pathogenesis (Z3)Organizers: Robert L. Modlin, Jenny P.Y. Ting & Foo Y. Liewjoint with Mechanisms of Pro-Inflammatory Diseases (Z4)Organizers: Virginia Pascual, Mark S. Anderson & Daniel KastnerApril 19–24, 2015 | Olympic Valley, California | USAThe Human Proteome (D7)Organizers: Matthias Mann, Mathias Uhlén, Catherine E. Costello & Albert J.R. HeckApril 24–29, 2015 | Stockholm | SwedenMechanisms of HIV Persistence: Implications for a Cure (E1)Organizers: Olivier Lambotte, Steven G. Deeks & Guido SilvestriApril 26–May 1, 2015 | Boston, Massachusetts | USAThe Arthropod Vector: The Controller of Transmission (E2)Organizers: Serap Aksoy, Stephen K. Wikel & David S. SchneiderMay 12–17, 2015 | Taos, New Mexico | USAHypoxia: From Basic Mechanisms to Therapeutics (E3)Organizers: Cormac T. Taylor, M. Celeste Simon, Sean P. Colgan & Roland H. Wenger May 12–17, 2015 | Dublin | IrelandHippo Pathway: Signaling, Development & Disease (E4)Organizers: Fernando D. Camargo, Kun-Liang Guan & Helen McNeillMay 17–21, 2015 | Taos, New Mexico | USAMicroRNAs & Noncoding RNAs in Cancer (E5)Organizers: Frank J. Slack, Manel Esteller & Lin HeJune 7–12, 2015 | Keystone, Colorado | USAAutophagy (E6)Organizers: Eric H. Baehrecke & Jayanta DebnathJune 19–24, 2015 | Breckenridge, Colorado | USA

FROm ThE ChAiR OF ThE BOARd

3

The 2015 Keystone Symposia meeting season was a year of strong attendance from more than 13,400 investigators across the world, hailing from 88 countries. A record number of 7,401 research abstracts were submitted for presentation at the diverse 57 meetings

listed on the facing page. Photos in this Annual Report of some of the research of the scientists who organized Keystone Symposia’s 2015 meetings, a two-year process undertaken on a completely volunteer basis, bear witness to the outstanding content of the meetings and the groundbreaking work being presented.

We celebrate the personal accounts, on pages 6-7, from some of the diverse investigators who have participated in the Keystone Symposia Fellows Program as well as attended conferences as a result of a scholarship or travel award. Developing the next generation of world-leading scientists is an important initiative of Keystone Symposia. Thanks to strong donor funding, the organization was able to increase the amount of support for student, postdoc and early-career investigator scholarships and travel awards, awarding 711 deserving recipients, up from 586 in 2014. And this donor support is also helping Keystone Symposia embark on a globalization plan described in more depth on the next page.

The 2016 season and fiscal year are my last serving as Chair of the Board of Keystone Symposia, a position I will miss immensely. But I will remain on the Board through June 2017 to facilitate the transition to a new Board Chair, Dr. Gary Nabel. I will also remain engaged as Head of the Scientific Advisory Board for the 2017 fiscal year. Gary is a highly respected immunologist and virologist who now heads research for Sanofi following a storied career at the NIH. He is very familiar with Keystone Symposia as head of its Scientific Advisory Board, a Board of Directors member since 2010, and a Scientific Advisory Board member from 2000 to 2009.

I would like to express sincere appreciation for all those who organize, present at, attend and support Keystone Symposia conferences. The organization would not be able to accomplish its mission of accelerating life science discovery without you.

Sincerely,

Juleen R. Zierath, Ph.D.Chair, Board of Directors, Keystone Symposia Professor, Karolinska Institutet

Raul Mostoslavsky, an Associate Professor at Harvard Medical School and the Massachusetts General

Hospital (MGH) Cancer Center, investigates the role of sirtuins in biological processes and disease states.

In March 2015, he served as lead organizer for the Keystone Symposia conference on Biology of Sirtuins co-organized with Shin-ichiro Imai, Marcia Haigis and Eric Verdin. This was the second time Keystone Symposia has held a meeting on the topic. In Dr. Mostoslavsky’s words: “The meeting showed the latest advances in the field of sirtuins, and how much we have progressed in the field in the past ten years, with now-clear molecular pathways identified that are modulated by sirtuins. This group of proteins represent a unique set of enzymes that influence broad biological processes (metabolism, DNA repair, development, lifespan, mitochondrial biology) in numerous species, thereby protecting against numerous diseases (cancer, neurodegeneration, diabetes, obesity). The meeting provided a fantastic atmosphere for discussion, forged new collaborations and set the stage for exciting novel discoveries in the near future.”

RAUL MOSTOSLAVSKY, M.D., Ph.D., BIOLOGY OF SIRTUINS

Immunofluorescence using a reporter of a glycolytic gene in intestinal crypts from in vitro-derived organoids (in red), showing that only intestinal stem cells are marked with the reporter. SIRT6-deficient organoids exhibit an increase in the number of these cells. Credit: Carlos Sebastian, postdoctoral fellow in the Mostoslavsky lab.

3

FROm ThE ChiEF ExECUTivE OFFiCER

Ana Maria Cuervo was one of three organizers along with Matej Orešič and

Antonio Vidal-Puig of the Systems Biology of Lipid Metabolism meeting in February 2015 and is also organizing Keystone Symposia’s June 2016 Autophagy meeting. Professor Cuervo runs a laboratory at the Albert Einstein College of Medicine in New York City that studies the role of protein degradation in neurodegenerative diseases and aging. The images at the left show intracellular accumulation of lipids when autophagy fails.

ANA MARIA CUERVO, Ph.D., LIPID METABOLISM AND AUTOPHAGY

Fiscal year 2015 was my first full year as President and CEO of Keystone Symposia. It was an honor to attend many of the conferences and experience first-hand the palpable sense of anticipation and excitement that they engender. It was also gratifying to experience strong

attendance from the scientific community as well as solid support from our corporate, foundation, government and individual donors. This support is vital to enable us to hold smaller conferences on basic science topics in the early stages of research as well as large, more translationally-focused meetings on more mature topics. It also enables us to offer scholarships and travel awards so that deserving early-career and LMIC investigators can participate.

As always, our conferences continued to be rated very highly for scientific quality, value participants gained from their attendance, and quality of our staff. Of the meeting participants responding to our survey in the 2014-2015 season, 92% rated the scientific quality of the meetings “Excellent” or “Very Good,” and 80% said that they made a contact at the conference they anticipate will result in a collaboration or sharing of information, data or techniques.

2015 was a year of change for the organization. Joining the team were a new head of Diversity in Life Science Programs, Dr. Irelene Ricks; Director of Digital Media, Nick Dua; and a new head of Development, Rick Sherman. Additionally, long-term staff member Jeannie Dalrymple moved to a new position as Senior Director of Global Development and her position as Director of Program Development and Implementation was filled by Allison Ogdon, also a staff member. The organization is well-positioned to embark on the growth and globalization plan that I started to implement in 2014. This plan calls for holding more of our conferences overseas, as well as increasing the overall number from 57 in 2015 to 60 in our 2016 season and up to 65 annually over the next decade. We will not sacrifice the quality of our conferences in this endeavor. Indeed, we will have periods of review to make sure that the quality always remains top-notch. In choosing locations for our conferences, we will ensure that the values of the host country are aligned with ours as well as making the science accessible. This means holding conferences in places that embrace diversity, respect scientific discourse, and are committed to providing safe, welcoming and healthy environments.

We have more work to do. In 2017 and 2018, we will be “Celebrating Diversity” by setting ourselves goals to increase the number of underrepresented investigators – including women – attending, speaking at and organizing our conferences. We will also feature some programs that will promote diversity at Keystone Symposia. We alone cannot solve this problem that pervades the life sciences and many other fields. But we must do our part and play a leadership role in striving for a higher standard.

In the nearly two years I have now been at Keystone Symposia, I have been impressed by the incredible dedication of all those involved – the staff; the volunteer scientists who serve on our Board and Scientific Advisory Board and organize and present at our meetings; and the donors who have many other worthy choices for their charitable funds. While a relatively small organization, Keystone Symposia has incredible global reach, and I look forward to seeing this grow.

Thank you for being part of the Keystone Symposia global community!

Sincerely,

Jane L. Peterson, Ph.D.President and Chief Executive Officer, Keystone Symposia

4

missiON ANd 2015 ACCOmPLishmENTs

Mission

Keystone Symposia will serve as a catalyst for the advancement of biomedical and life sciences by connecting scientists within and across disciplines at conferences and workshops held at venues that create an environment conducive to information exchange, generation of new ideas, and acceleration of discoveries that benefit society.

Notable Achievements and Milestones in Fiscal Year 2015

FFY15 featured 57 meetings across a diverse range of the life sciences that attracted the participation of 13,417 scientists from all over the world (87 countries). The majority of scientists were affiliated with academia (68%), with the others (25%) coming from industry, government and nonprofit/nongovernment organizations (7% of participants did not disclose

their affiliation). FY15 student and postdoc participation was 41%. The majority of attendees (68%) who disclosed year of birth were under 45 years of age. In general, attendee demographics were similar to those of the previous two years. Some notable achievements and milestones included:

• Keystone Symposia awarded 466 scholarships for meeting attendance to deserving graduate students and postdoctoral fellows, funded by its own operating fund as well as generous donor support.

• Women were well-represented among scholarship recipients (54%). Ninety-eight scholarships were awarded to students and postdoctoral fellows from underrepresented backgrounds. The majority of those recipients were Hispanic American (55%) and African American (26%).

• Thanks to support from the Bill & Melinda Gates Foundation and the São Paulo Research Foundation (FAPESP), 216 investigators and clinicians from developing countries received Global Health Travel Awards enabling them to attend infectious disease meetings in the 2015 Keystone Symposia Global Health Series. Keystone Symposia’s Global Health Series will continue through 2018 thanks to a renewal of the generous Bill & Melinda Gates Foundation grant.

• Keystone Symposia held its first conference in Copenhagen, Denmark (“Lipid Metabolism and Diabetes”) and in São Paulo, Brazil (“Cell Death Signaling”).

• Exit survey respondents gave high ratings for professional development opportunities at the Keystone Symposia conferences regardless of career stage, affiliation or meeting role. Eighty percent agreed that they made a useful contact at the conference they attended that will lead to a collaboration or sharing of information, data or techniques. Similarly, respondents recognized that the meeting had potential to impact their research regardless of career stage or affiliation. Eighty-eight percent of attendees agreed that the conference facilitated interactions between junior and senior investigators.

• Exit survey respondents reported very high ratings for the scientific content of the meetings regardless of age, region, affiliation or occupation, continuing the same trend observed over the last few years. Ninety-two percent of participants rated the scientific content “Excellent” or “Very Good.”

• Keystone Symposia conducted two public forums for the Summit County, Colorado community with panels of experts drawn from scientific conference speakers: on “The Viral Threat in the Age of Ebola” on January 13, 2015, and on “Little Guys, Big Jobs: Microbes at Work in Your Body” on March 3, 2015.

Martin Myers, Professor of Diabetes Research at the University of Michigan

and Director of the Michigan Diabetes Research Center, studies action of the hormone leptin and neural mechanisms underlying the response to hypoglycemia. In April 2015, he co-organized a meeting on Neuronal Control of Metabolic Physiology and Diseases with Dongsheng Cai. The photo at left shows EGFP-L10a-containing leptin receptor neurons in the hypothalamus.

MARTIN MYERS, Ph.D., NEURONAL CONTROL OF METABOLIC PHYSIOLOGY AND DISEASES

5

sPOTLighT ON divERsiTy – in their own words

Whether through providing scholarships for deserving students and postdoctoroal fellows, or the Fellows Program, a unique year-long mentoring and education program for Assistant Professor-level scientists from underrepresented backgrounds, Keystone Symposia is dedicated to embracing diversity. Here a few of the beneficiaries of these

programs share their value, in their own words:

De’Broski R. Herbert, Ph.D. (Keystone Symposia Fellow, Class of 2008)Associate Professor of Infectious Immunology, University of Pennsylvania

Over the course of my doctoral training in parasitology and cellular immunology, I was first introduced to the Keystone Symposia in 2000, where I was selected to give my

first international lecture in the short-talk format. This exposure facilitated my interactions with a broad cross-section of leaders within the scientific disciplines of Type 2 immunity, infection and immunology. It was therefore with great enthusiasm that I served as one of the first Keystone Symposia fellows in 2008. Although unsure of the tangibles at first, I immediately began to benefit from participating in this program. This opportunity afforded a more intimate understanding of the history and organizational structure responsible for creating Keystone Symposia’s premier scientific meetings. Not only did the Fellows Program provide an enlightened view of how Keystone Symposia has become a 44-year success, but it also greatly accelerated the pace of my own career development.

My participation as a Keystone Symposia Fellow and now as an SAB (Scientific Advisory Board) member has provided a unique environment to interact with the current thought leaders in biotechnology, industry and academic sectors in an intimate and highly effective setting. Such interactions have made it possible to participate in mentoring relationships and networking and to also secure unique biological reagents that would have otherwise not been possible. Moreover, the recognition of my participation in Keystone Symposia has facilitated rapid academic promotion and increased university responsibilities. As an African-American male scientist, who has been able to successfully compete for numerous federal and private foundation awards, I credit the Keystone Symposia Fellows Program as a major factor in my success thus far. In aggregate, I consider my past and current roles in this organization as one of the most influential parts of my scientific career that has facilitated expansion amid a time of considerable financial turmoil, which is absolutely priceless.

Jeanine Amacher, Ph.D. (Scholarship Recipient)Postdoctoral Researcher, Molecular and Cell Biology, University of California, Berkeley

The opportunity to attend The Biological Code of Cell Signaling: A Tribute to Tony Pawson meeting was an extraordinary start to my postdoc. I had only been in my postdoc lab for 6 months when the meeting occurred in January 2015, and was still

learning about the field of signaling proteins, specifically tyrosine kinases and ubiquitylation. Every talk at the meeting was given by an all-star in the field – these were the people who discovered the proteins and pathways I study! The small size of the meeting facilitated engaging discussions at my poster, and I was able to form relationships with scientists whose work is the reason I chose my postdoc lab. In addition, there were a number of scientists from both academia and industry, as well as many representatives from various scientific journals, providing networking opportunities and encouraging conversations about career development. The picturesque setting of Steamboat Springs, Colorado was wonderful, and ample free time in the afternoon to ski and snowshoe contributed to the atmosphere of the week. As a young postdoc, it can be hard to envision your transition to the career investigator stage, and this meeting was especially unique because colleagues of Tony Pawson told wonderful stories about the “early days” of cell signaling research, and how they achieved their esteemed positions. The Keystone Symposia scholarship program is an excellent way for young investigators, like me, to attend these extremely beneficial meetings, presenting and learning about interesting science in beautiful locations.

6

7

Michaela Patterson Ph.D. (Scholarship Recipient)Postdoctoral Fellow, University of California, San Francisco

I can honestly say that the Keystone meeting, Heart Disease and Regeneration: Insights from Development, was the most rewarding and productive conference I have ever attended. The size of the meeting and the overall mentality of the attendees (PIs in

particular) really created an inviting and inclusive dynamic for the more junior scientists, without detracting from the cutting-edge science. We were strongly encouraged to participate, whether during post-talk questions, meals, or poster sessions. And for the first time in my career I really felt like I had made some successful networking connections and collaborations with some of the top scientists in the field. I look forward to the opportunity to attend another Keystone Symposium.

Kolawole Fasakin, M.S. (Global Health Travel Award Recipient)Chief Biomedical Scientist & HIV/AIDS Researcher, Federal Teaching Hospital, Ekiti, Nigeria

My experiences were great. It’s nice attending such a rigorous academic, molecular-based symposium. The pre-conference workshop enabled us to understand the presentation at the symposium better. Great discoveries and progress I observed

in the development of HIV vaccines should mean we are getting nearer to HIV prevention and cure. Poster presentation and opportunities to interact with presenters gave room for collaboration and sharing of experiences.

Cherié Butts, Ph.D. (Keystone Symposia Fellow, Class of 2008)Associate Director, Immunology Research Program, Biogen, Cambridge, Massachusetts

The Keystone Symposia Fellows Program has been transformative in my development as a scientist – offering quality professional opportunities and

strengthening personal interactions. I was familiar with Keystone Symposia, having presented at conferences, but was unaware of the conference development process. Participating in the Scientific Advisory Board (SAB) Study Groups provided insight into the critical nature of conducting research on important scientific questions; being innovative; and having a reputation for working well with others. These were all fundamental factors in selecting conference organizers and likely played a role in my nomination to organize a 2017 Keystone Symposia conference. Our brief presentations to the SAB highlighted the significance of focusing upon key themes, which would result in my giving oral presentations (2009, 2011) and serving a role as host for mentoring workshops (2012-2015) at Keystone Symposia conferences. The Fellows Program also introduced us to industry leaders that would ultimately lead to an employment opportunity for me. I had not previously considered a career in the industry sector and have identified talents I possess beyond the bench with this new experience.

The Keystone Symposia Fellows Program brings together individuals from across the United States with expertise in a variety of scientific fields (e.g., cancer biology, engineering, immunology, neuroscience). Although our focus in biomedical research differed, our experiences were surprisingly similar. We were “Mavericks”: often the first or only in our family to study science; the first or only in our family with an advanced degree; the only underrepresented (UR) individual in graduate school; and/or the only UR scientist in our department. These common experiences created a strong bond and sense of relief from the social isolation that many UR researchers experience. We could openly discuss our workplace frustrations and joys. We could offer advice on navigating difficult situations in the context of our unique demographic. We could brainstorm new scientific ideas without fear of replication. Most importantly, the network created by the Keystone Symposia Fellows Program became a platform for 360-degree mentoring of the next generation of UR scientists and an opportunity for me to focus mentoring efforts on a more defined group of biomedical researchers.

8

2015 EXPENSE BREAKDOWN

The charts below are intended to provide a snapshot of Keystone Symposia’s 2015 finances and activities. Please visit keystonesymposia.org/AboutUs/AnnualReport.cfm to view the full audited statement of financial condition and statement of activities for the fiscal year July 1, 2014 – June 30, 2015.

2015 STATEMENT OF ACTIVITIES

Investment Income/Miscellaneous Income (1.97%)

Contributions (17.84%)

Government Grants (4.38%)

Fees/Earned Income(75.02%)

FiNANCiAL sNAPshOT OF ThE yEAR

Educational Programs (68.62%)

Fundraising & Development (4.98%)

Management & General (26.40%)

Temporarily Permanently Unrestricted Restricted Restricted Total

Revenues

Registration revenue and other $ 10,476,012 $ – $ – $ 10,476,012 net of scholarships of $470,150 Government grants 722,403 – – 722,403 Contributions 1,328,888 1,193,002 32,170 2,554,060 Net investment income 275,207 193 275,400 Net assets released from restrictions 2,203,538 (2,203,538) – Total revenues 15,006,048 (1,010,343) 32,170 14,027,875 Expenses

Program expenses 9,256,328 – – 9,256,328 Management & general expenses 3,561,335 – – 3,561,335 Fundraising expenses 671,557 – – 671,557 Total expenses 13,489,220 – – 13,489,220 Return of Fund to Donors – (62,919) – (62,919) Change in Net Assets 1,516,828 (1,073,262) 32,170 475,736 Net Assets – Beginning of Year 11,485,602 2,859,365 – 14,344,967 Net Assets – End of Year $ 13,002,430 $ 1,786,103 $ 32,170 $ 14,820,703

68.62% of Keystone Symposia’s expenditures in fiscal year 2015 went toward educational programs including meeting programs, scholarships, travel awards and diversity initiatives.

2015 REVENUE BREAKDOWN

Investment Income/Miscellaneous Income (1.97%)

The image at right provided by Serap Aksoy (left) depicts a pregnant female

tsetse fly (Glossina morsitans), the sole vector of Human African Trypanosomiasis (also known as sleeping sickness) in sub-Saharan Africa. In advanced stages, the disease attacks the central nervous system and can cause death if untreated.

The image below right is of Ixodes scapularis, the vector of Lyme Disease, provided by Stephen Wikel (below left).

Drs. Aksoy and Wikel were two of the organizers, along with David Schneider, of the May 2015 conference on The Arthropod Vector: The Controller of Transmission. According to Dr. Aksoy, the conference was important in “providing the opportunity to exchange knowledge on the state-of-the-art concepts and techniques to prevent insect-transmitted diseases globally.”   Dr. Aksoy is Professor of Epidemiology in the Department of Epidemiology of Microbial Diseases at Yale School of Public

Health. She has built a broad program for investigations on tsetse flies and African trypanosomes, with direct implications and links for disease control in Africa. The overarching paradigm for her program is the interdisciplinary approach to investigation of disease transmission – ranging from basic research on vector and parasite biology in the laboratory to the population genetics/genomics of the vector and parasite in natural populations, and disease epidemiology in the field – in order to develop innovative control methods. Dr. Aksoy has led an international consortium, International

Glossina Genome Initiative (IGGI), to develop genetics and genomics knowledge of tsetse flies since 2004, and together with her collaborators in Kenya and Uganda works to build research capacity in tsetse-transmitted diseases in sub-Saharan Africa. Dr. Aksoy is a Fellow and Council Member of the American Society of Tropical Medicine and Hygiene and co-Editor-in-Chief of PLOS Neglected Tropical Diseases.

Dr. Wikel is Senior Associate Dean, Professor and Chairman in the Department of Medical Sciences, and St. Vincent’s Medical Center Endowed Chair in the School of Medicine, at Quinnipiac University in Connecticut. His research interests, for over 40 years, are focused on host immunological responses and vector countermeasures at the arthropod vector-host-pathogen interface and the role of those interactions in blood feeding and pathogen transmission.

SERAP AKSOY, Ph.D. and STEPHEN WIKEL, Ph.D., INSECT-BORNE DISEASES

sCiENTiFiC ORgANiZER & mEETiNg sPOTLighT

Sean Colgan, Ph.D. was one of the organizers of the May 2015 conference on Hypoxia: From Basic Mechanisms to

Therapeutics in Dublin, Ireland co-organized with Cormac Taylor, Celeste Simon and Roland Wenger.

This image from Dr. Colgan’s lab depicts localization of hypoxic regions in the healthy mouse colon. Shown here is analysis of pimonidazle dye retention (red) along the length of the crypt-villus axis. Cell nuclei (blue) are stained for orientation. The image demonstrates the concept of “physiologic hypoxia” in which the colonic mucosa normally exists in low oxygen conditions along the luminal aspect. Dr. Colgan is the Joel Levine-Fred Kern, Jr. Professor of Medicine and Immunology at the University of Colorado School of Medicine, Vice Chair for the Department of Medicine and the Director of the Mucosal Inflammation Program. His research is focused on the identification of novel anti-inflammatory molecules associated with innate immune responses in mucosal inflammation.

SEAN COLGAN, Ph.D., HYPOXIA

9

Photo courtesy of Geoffrey Attardo, Yale School of Public Health

Vincent Christoffels investigates heart development at the Academic Medical Center in Amsterdam as Professor

of Developmental Biology and Chair of the Department of Anatomy, Embryology and Physiology. He particularly focuses on the transcriptional control of cardiac development and conduction.

In March 2015, he served as lead organizer for the Keystone Symposia conference on Heart Disease and

Regeneration: Insights from Development co-organized with James Martin and Deborah Yelon. This was held jointly with the conference on Cell Biology of the Heart: Beyond the Myocyte-Centric View co-organized by Peter Kohl, Robert Gourdie and Stefanie Dimmeler.

The photos to the left show whole-mount fluorescence microscopy of a double transgenic mouse embryo (Nppb-Katushka/Tbx3-eGFP). In the photo at near left, the conduction system of the heart is illuminated in green fluorescent protein and the atria and ventricles in red fluorescent protein.

VINCENT CHRISTOFFELS, Ph.D., HEART REGENERATION, and PETER KOHL, Ph.D., CARDIAC CELL BIOLOGY

DOUGLAS MASHEK, Ph.D., NAFLD

sCiENTiFiC ORgANiZER & mEETiNg sPOTLighT

10

Ruth Ley was one of the co-organizers of the Keystone Symposia meeting

on Gut Microbiota Modulation of Host Physiology: The Search for Mechanism in Keystone, Colorado in March 2015, along with Fredrik Bäckhed and Yasmaine Belkaid.

Dr. Ley, an Associate Professor at Cornell University, leads a research group that works on the role of gut microbiota in human health and disease, and the relationships between host genetic

variation and microbiome diversity in humans and maize. A recipient of the NIH Director’s New Innovator Award and ISME Young Investigator Award, she is already a pioneer in the rapidly expanding field of microbiome research.

The image above shows one of the organisms Dr. Ley’s lab is studying, Christensenella minuta, which is a human gut bacterium that reduces weight and adiposity gains in a gnotobiotic mouse model.

Peter Kohl was lead organizer of the joint meeting on Cell Biology of the Heart: Beyond the Myocyte-Centric View. He is currently the Chair

in Cardiac Biophysics and Systems Biology at the National Heart and Lung Institute, Imperial College of Science, Technology and Medicine in London. A Fellow of the American Heart Association and Heart Rhythm Society, as well a Senior Fellow of the British Heart Foundation, he previously set up the Oxford Cardiac Mechano-Electric Feedback lab and is an expert in cardiac mechano-electrical interaction studies.

The image at right depicts cardiac myocyte-nonmyocyte ultrastructural links, as seen with 3D EM tomography. Image courtesy of Dr. Eva Rog-Zielinska, National Heart and Lung Institute, Imperial College London.

RUTH LEY, Ph.D., GUT MICROBIOME

In March 2015, Keystone Symposia held its first conference on Optogenetics in Denver, Colorado organized by Edward Boyden, Associate Professor of Biological Engineering

and Brain and Cognitive Sciences at the MIT Media Lab and the MIT McGovern Institute (shown at left); Klaus Hahn, Professor of Pharmacology at the University of North Carolina at Chapel Hill, and Chandra Tucker, Assistant Professor of Pharmacology at the University of Colorado School of Medicine (shown at right). Dr. Boyden, who was named to Wired’s Smart List of “50 People Who Will Change the World” and the Technology Review World’s “Top 35 Innovators under Age 35” list, leads a Synthetic Neurobiology Group which develops tools for analyzing and engineering the circuits of the brain. These include “optogenetic” tools which enable the activation and silencing of neural circuit elements with light 3-D microfabricated neural interfaces that enable control and readout of neural activity, and robotic methods for

automatically recording intracellular neural activity and performing single-cell analyses in the living brain. Dr. Tucker’s research focuses on developing novel optogenetic tools for probing cellular function and protein interactions. She pioneered the use of the photoreceptor cryptochrome as an optogenetic tool, and has developed systems to modulate protein-protein interactions and induce or block protein function with light. Of the conference, she said, “This was the largest meeting to date in this emerging field of optogenetics, and I think it was instrumental at bringing people together. I have already heard of a number of collaborations that were initiated at this meeting and even one instructional course.”

Dr. Boyden’s image below left shows opsins opening when blue light hits a neuron. Dr. Tucker’s images at the right demonstrate the use of the photoreceptor cryptochrome tool she developed. More specifically, it shows mCherry-tagged CRY2olig, an optogenetic actuator derived from plant cryptochrome, with diffuse localization in HEK293 cells at the left, then undergoing robust clustering within seconds after blue light stimulation on the right.

pre-blue light post-blue light

DOUGLAS MASHEK, Ph.D., NAFLD

Douglas Mashek was one of the co-organizers along with Jay Horton and Brian Finck of Keystone Symposia’s first conference on Liver

Metabolism and Non-Alcoholic Fatty Liver Disease (NAFLD). This conference was held jointly with the conference on Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure in March 2015. Dr. Mashek is Associate Professor of Nutrition at the University of Minnesota who studies fatty acid trafficking and signaling with an emphasis on hepatic lipid droplet biology. Specifically, his research laboratory is attempting to define NAFLD on a more molecular level and characterize how alterations in lipid droplet proteins influence cell signaling pathways linking NAFLD to its comorbidities. The image at the left shows lipid droplets in primary hepatocytes transfected with YFP-tagged perilipin 5.

11

ED BOYDEN, Ph.D. and CHANDRA TUCKER, Ph.D., OPTOGENETICS“

Human lung tumors consume glucose to produce energy and macromolecules, as indicated by enhanced uptake

of fluorodeoxyglucose (FDG) imaged clinically by positron emission tomography. However, the extent of metabolic heterogeneity among individual human tumors is unknown. The lab of Ralph DeBerardinis at The University of Texas Southwestern Medical Center assessed glucose-dependent metabolic fluxes to show that human lung tumors are highly heterogeneous in their metabolism of glucose and other fuels, and that the tumor microenvironment influences metabolic flux, even within distinct regions of the same tumor.

Dr. DeBerardinis is a pediatrician and a medical geneticist who diagnoses and treats children with inborn errors of metabolism, rare diseases that impair the ability to derive energy from sugars, amino acids and fats. Over the years, it has become apparent that cancer is also caused by altered metabolism. His lab’s work developing techniques to analyze metabolism in cancer cells and live tumors, including in human patients, has led to the discovery of a number of metabolic pathways that support cancer cell survival and growth, including pathways that escaped notice despite more than a century of research in metabolism. His lab’s goals are to identify metabolic disturbances in cancer and other diseases, understand how those disturbances interfere with normal cellular function, develop new diagnostic methods to monitor them in patients, and design new therapies to restore normal metabolism and improve health. The January 2015 conference he co-organized with Robert Abraham and Eyal Gottlieb called Integrating Metabolism and Tumor Biology, held in conjunction with the conference on PI 3-Kinase Signaling Pathways in Disease, was a step in this important biomedical direction.

RALPH DEBERARDINIS, M.D., Ph.D., TUMOR METABOLISM

sCiENTiFiC ORgANiZER & mEETiNg sPOTLighT

12

Eric Baehrecke was the lead organizer of Keystone Symposia’s June 2015 meeting on Autophagy, co-organized with Jayanta Debnath, and was appointed to the Keystone Symposia Scientific Advisory Board beginning

July 1, 2015. Dr. Baehrecke is a Professor in the Department of Molecular, Cell and Cancer Biology at the University of Massachusetts Medical School. His team studies the regulation and function of autophagy

in cell survival and cell death in animals, and the mechanisms controlling non-apoptotic cell death.

While at the meeting in Keystone, Dr. Baehrecke participated in a lively videotaped roundtable discussion on autophagy that will be published in 2016 on the Keystone Symposia YouTube channel. From left to right, the images below show: 1) Plasma membrane (in red) and autophagy, or self-eating, structures (in green) in the intestine; 2) saliva gland microRNA (in green) induces autophagy (in red); and 3) autophagy-deficient cells (in magenta) are larger in the intestine. In all images, DNA is in blue. The image at the left is from Charles Nelson in Eric Baehrecke’s laboratory and published in Molecular Cell in 2014. The other two images are from Tsun-Kai Chang, also in the Baehrecke lab.

ERIC BAEHRECKE, Ph.D., AUTOPHAGY

Keystone Symposia benefits from generous financial support from the biotechnology, pharmaceutical and associated industries, charitable foundations, scientific societies, and individual friends of the institution, as well as from the NIH and other US and foreign government agencies. This support is used primarily to fund scholarships for graduate students and

postdoctoral fellows, to finance travel awards for scientists from low- and middle-income countries (LMICs), and to subsidize travel and lodging costs for speakers from academic and other nonprofit institutions.

For the fiscal year 2015, we recognized $4.33 million* in support of current operations from corporate, foundation, government and individual sources, as shown in the chart below. The organization gratefully acknowledges this support because it allows Keystone Symposia to continue to serve as a preeminent catalyst for the advancement of biomedical sciences by convening open, international, peer-reviewed meetings across the globe.

If you are interested in learning more about supporting Keystone Symposia, please contact me at 1 (970) 262-2695, or at ricks@keystonesymposia.org. To make a gift online in support of Keystone Symposia’s Future of Science Fund, please visit www.keystonesymposia.org/ScienceFund.

Rick ShermanVice President of Development, Keystone Symposia

*Donor support includes amounts reflected in the statement of activity from contributions, government grants and net assets released from restriction in the unrestricted fund in addition to the contribution to the permanently restricted fund. Temporarily restricted contributions were not included in this pie chart. Nor were in-kind marketing and advertising contributions, in contrast to past annual reports.

13

dONOR sUPPORT

Corporate Gifts: 50%

Foundation Gifts: 22%

US Federal Government Grants: 15%

Other Government Grants: 6%

In-Kind Gifts: 3%Individual Gifts: 2%

Academic Journal Gifts: 2%

CHAMPIONSTop-tier donors making an ongoing, annual commitment of $100,000+. Their public championing of Keystone Symposia’s cause provides inspirational leadership commitment to our shared scientific mission of catalyzing collaborations, accelerating discoveries, and preparing and positioning the next generation of leading life scientists.

Educational donation provided by Amgen*Bayer HealthCare Pharmaceuticals*Bill & Melinda Gates FoundationGenentech, Inc.*Merck & Co., Inc.*Minas Gerais State Agency for Research Development (FAPEMIG) – BrazilNovo Nordisk A/S*

SUSTAINING BENEFACTORSDonors making a three-year commitment of at least $50,000 per year. Their generous support is crucial to sustain Keystone Symposia’s ability to plan future scientific conferences focused on emerging topics and excellence in science.

AstraZeneca*BioLegend, Inc.*Cell Research*Incyte Corporation*

BENEFACTORSDonors of $50,000 or above. We are very grateful for their extraordinary commitment to our mission to connect the scientific community and accelerate discoveries that benefit society. Special thanks to those organizations that provide consistent, annual Benefactor-level support.

Elsevier*Science Foundation Ireland

SUSTAINING SPONSORSDonors making a three-year commitment of $25,000 to $49,999 per year. Their generous support is crucial to Keystone Symposia’s ability to plan future scientific conferences focused on emerging topics and excellence in science.

Abide Therapeutics Inc.*Arena Pharmaceuticals, Inc.*Astellas Pharma Inc.*Boehringer Ingelheim Pharmaceuticals, Inc.*Educational grant from Celgene Corporation*Cell Signaling Technology, Inc.*Constellation Pharmaceuticals*Curemark LLC*Editas Medicine*FORUM Pharmaceuticals Inc.*Gilead Sciences, Inc.*H3 Biomedicine Inc.*ImmunoGen, Inc.*Infinity Pharmaceuticals, Inc.*Intercept Pharmaceuticals, Inc.*

The listings on this page and the next five pages reflect donations for the fiscal year beginning July 1, 2014 and ending June 30, 2015.

14

*Indicates a gift to the Directors’ Fund, which allows Keystone Symposia’s President/CEO and Directors to schedule and support meetings in the early stages of research.

dONOR sUPPORT

Pfizer Inc.* Roche* São Paulo Research Foundation (FAPESP) – Brazil Science for Life Laboratory – Stockholm Knut and Alice Wallenberg Foundation

Journal of Molecular Cell Biology (JMCB)*Regeneron Pharmaceuticals, Inc.*Takeda Pharmaceutical Company Limited*Thermo Fisher Scientific Inc.*

MedImmune* Mersana Therapeutics* NeoStem, Inc.* Nestlé Institute of Health Sciences* Novartis Institutes for BioMedical Research* OncoMed Pharmaceuticals, Inc.* Sangamo BioSciences, Inc.* Shire Human Genetic Therapies* TESARO, Inc.* Theravance Biopharma* Vertex Pharmaceuticals Incorporated*

The listings on this page and the next five pages reflect donations for the fiscal year beginning July 1, 2014 and ending June 30, 2015.

15

PARTNERS, PATRONS, DONORS AND CONTRIBUTORS

Keystone Symposia wishes to thank the following donors to the 2015 meeting series. Their generous support makes possible the outstanding scientific quality of our meetings and unsurpassed opportunities for interaction among attending scientists.

PARTNERS($10,000–$24,999)

Baker Ruskinn*Biosearch Technologies

PATRONS

SPONSORSDonors contributing $25,000 to $49,999. These generous gifts allow us to convene meetings in a wide variety of important areas. Special thanks to those organizations that provide consistent, annual Sponsor-level support.

AbbVie Inc.*Agilent Technologies, Inc.*Biogen*Bristol-Myers Squibb Company*California Institute for Regenerative Medicine (CIRM)Genmab A/S*GlaxoSmithKline*Gordon and Betty Moore Foundation

($5,000–$9,999)

Abcam plc*Adipogen International*Avanti Polar Lipids, Inc.*Bethyl Laboratories, Inc.*BMG LABTECH Ltd.*CEDARLANE*Chroma Technology Corporation*Coy Laboratory Products Inc.*Dharmacon, part of GE Healthcare*Don Whitley Scientific LimitedeBioscience, an Affymetrix company*The Endocrine Society

Ionis Pharmaceuticals, Inc.*Janssen R&D: Pharmaceutical Companies of Johnson & Johnson*Educational grant from Lilly*Monsanto Company*Sarepta Therapeutics*Taylor & Francis*

Exiqon A/S* HypOxygen* Inventiva* Luxcel BioSciences Ltd.* Mabtech Inc.* Merck Serono/Merck* Oxford Optronix Ltd.* Rigel Pharmaceuticals, Inc.* Seahorse Bioscience, Inc.* Sigma Life Science* TriLink Biotechnologies* Zymo Research Corporation*

DONORS($2,500–$4,999)

ALPCO Diagnostics*American Heart Association’s Councils on Basic CV Sciences, CV Disease in the Young, and Functional Genomics and Translational BiologyBioVentures, Inc.*Cambridge Isotope Laboratories, Inc.*Canadian HIV Vaccine Initiative Research*Cayman Chemical Company*Dove Medical Press Ltd*Dow AgroSciencesEssential Pharmaceuticals*Fáilte IrelandFibroGen Incorporated

CONTRIBUTORS(up to $2,500)

DuPont PioneerEchelon Biosciences, Inc.Intelligent Imaging Innovations (3i)

ISOTEC, a member of the Sigma-Aldrich Group*Journal of Lipid Research KWS SAAT AG*miRagen Therapeutics*Mucosal Immunology Studies Team (MIST)Opsona Therapeutics Ltd*Promega Corporation*ProSci Inc.*R&D Systems, a Bio-Techne brand*RaNA Therapeutics Inc.*Research Diets, Inc.*Rijk Zwaan Zaadteelt en Zaadhandel B.V.Zoetis

March of Dimes Foundation, Grant No. 4-FY14-523

New Era Enterprises, Inc.*PLOS Biology

US GOVERNMENT GRANTS

Keystone Symposia appreciates grants to support various 2015 meetings received from the following government agencies:

National Institutes of Health (NIH):National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI) National Human Genome Research Institute (NHGRI) National Institute on Aging (NIA) National Institute of Allergy and Infectious Diseases (NIAID) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institute of Environmental Health Sciences (NIEHS)National Institute of Food and Agriculture (NIFA), USDANational Institute of General Medical Sciences (NIGMS)National Institute of Neurological Disorders and Stroke (NINDS) Office of the Director (OD)

National Science Foundation (NSF)

16

dONOR sUPPORT

DIVERSITY PROGRAM SUPPORT

Keystone Symposia is grateful to the following 2015 supporters of its Diversity in Life Science Programs.

BiogenThe Endocrine SocietySanofi US

The following companies generously agreed to forego reimbursements for speaker travel and lodging expenses in order to support 2015 Keystone Symposia meeting programs.

AB SCIEXAbbVie Inc.Amgen Inc.AstraZeneca Pharmaceuticals, L.P.Biogen IdecBioNTech RNA Pharmaceuticals GmbHCelgene CorporationCelldex Therapeutics, Inc.Cellular Dynamics InternationalConstellation PharmaceuticalsCSL LimitedDAIICHI SANKYO CO., LTD.Dynavax Technologies CorporationEli Lilly and CompanyEmber TherapeuticsEpizyme, Inc.Genentech, Inc.Gilead Sciences, Inc.GlaxoSmithKlineHeptares Therapeutics LtdImmatics Biotechnologies GmbH

SPEAKER GIFT-IN-KIND DONORS

InventivaIonis Pharmaceuticals, Inc.Janssen R&D: Pharmaceutical Companies of Johnson & JohnsonMedImmuneMerrimack PharmaceuticalsMolecular Partners AGNeoStem, Inc.New England Biolabs, Inc.Novartis Institutes for BioMedical ResearchNovartis Pharma AGNovartis Vaccines and DiagnosticsPfizer Global Research & DevelopmentPfizer Inc.RaNA Therapeutics Inc.Regeneron Pharmaceuticals, Inc.Roche Diagnostics GmbHSangamo BioSciences, Inc.

17

These generous alumni of previous meetings and others with a passion for ensuring a future of scientific discovery that benefits humankind have made gifts in the fiscal year ending June 30, 2015 to support the Keystone Symposia Future of Science Fund. Through their generosity, we are able to provide scholarships and travel awards to the next generation of biomedical and life scientists, whose education and careers are enhanced by the opportunity to attend meetings and interact with the world’s leading senior scientists.

PRESIDENT’S CIRCLE ($10,000+)The Elkes Foundation

FOUNDERS’ SOCIETY ($5,000–$9,999)

KEYSTONE CHAMPIONS ($1,000–$4,999)Dr. Edward A. DennisPhilip GregoryWalter Moos and Susan MillerJane L. Peterson and Kenneth J. CremerAlessandro PocaiSidney E. Frank Foundation in honor of Terry OpgenorthTachi and Leslie Yamada with matching gift from Takeda Pharmaceuticals U.S.A., Inc.Juleen ZierathAnonymous (1)

KEYSTONE BENEFACTORS ($500–$999)SK Dey, Division of Reproductive Sciences, Cincinnati Children’s Research Foundation Gary Nabel

KEYSTONE PATRONS ($100–$499)Manal Abdelmalek, MD, MPHAlan AttieArthur BeyderAmanda BrownLinda S. CauleyCarl ClassenPamela S. Daugherty*Thomas Dubensky, Jr.Eric Parker with matching gift from Merck Partnership for GivingOlivera J FinnJanusz Franco-Barraza*Glenn FriedrichDwight GermanHenry GinsbergNancy L. HaigwoodSharath HegdeL. Eric HuangKiyo-aki IshiiYoung Ho JeonWilliam KilembeRolf KletzienMasayasu KojimaTakeshi KuroseDavid LivingstonPatricia LiWangThomas Alexander LutzDieter MansteinMark H. KaplanDavid MartinAllan Murray

Masakazu Namihira Annelise Nguyen Donal O’Gorman Alexander Pertsemlidis Edward B. Sanders Anish Senmajumdar Shohei Koide Malu Tansey James Thomas James Trager Sally Wenzel Xiaoyong Yang Reza Zarnegar Ann Zovein Anonymous (3)

KEYSTONE CONTRIBUTORS ($10–$99) Joe Alcock Cody Allison Zita Arany Kenichi Asano Than Aung Xiucong Bao Afrouz Behboudi Carolyn Behm Kathrin Bernt Sylvie Bertholet Bonnie B. Blomberg Linda B. Bloom Jean-Paul Borg Kerstin Borgmann Rachel Brewster Peter Bunyard Wendy Burgers Coby Carlson Michael Carrithers Teja Celhar Sandra Chang Rattawit Changlek Wei-June Chen Elena Chertova Yeon Kyung Choi Alessio Ciulli Kevin Clancy German Contreras Tânia Creczynski-Pasa Enrico Dainese Mary Ann De Groote Renee de Pooter Alexandre Deshiere Giusy Di Conza Victor Dillard Tzvetanka Dinkova George Dubyak

Christoph Ellebrecht Doriano Fabbro Karine Fenelon Katrin Fischer Jacqueline Flynn Mary Foster Adam Frost Jessica Fry Lindsay Fry Lucio Gama Evgenia V. Gerasimovskaya Zach Gerhart-Hines Troy Ghashghaei Johan Gobom David Graber Gillian Gray Charles Grose Gloria Guerrero Guenter Haemmerle Dale Hamilton Bassem Hassan Susanne Heinzel Jiri Hejnar Frankie Heyward Johanna Hol Morley D. Hollenberg Navin Horthongkham Samuel Hunter Rahizan Issa Nathalie Jacobs Youngnam Jin* Matthew Justice Thomas Kietzmann Chang-Yub Kim InKyeom Kim Toshio Kitawaki Suneil Koliwad Kevin Koronowski Sang Ah Lee Seung-Pyo Lee Andrew M. Leidal Qibin Leng Aurelia Lewis Baoguo Li Jennie Lill Xinhua Lin Pam Lincez Qun Lu Steven K. Lundy Ivan Luptak Therese Lynn Kathryn Malecek Pankaj Mandal Robert Mays Craig McCormick

FUTURE OF sCiENCE FUNd dONORs

18

KEYSTONE CONTRIBUTORS (continued) Wladek Minor Masayuki Miyasaka Shabnam Mohandessi Ravikanth Nanduri Nana Owusu-Boaitey Alessandra Pernis Mark Philips Raju Pillai Laszlo Radvanyi Ponni Rajagopal Florian Richter Carola Ries

Miguel Rivera Kaori Sakamoto Jacob C. Schwartz Gregg Siegal Sandra C. Souza Lucinda Steward Paula Tabares Atsushi Tanaka Simeon Taylor Nikeya Tisdale David Topham James Tsai Sander Van Den Heuvel Giles Vick

James Wang Qunwei Wang Dirk Werling Johnathan Whetstine Michael Wrzaczek Li Wu Sheng-Jiun Wu Lei Yin Voot Yin Dietmar Zehn Elisa Zhang Guigen Zhang Anonymous (1)

FUTURE OF sCiENCE FUNd dONORs

ThE KEysTONE sOCiETyCHARTER MEMBERSJim and Sue AikenChristopher AtwoodAnish and Sushmita Sen Majumdar

In 2012, Keystone Symposia formed a new society to recognize meeting alumni and friends who make estate contributions (e.g., simple bequests, planned gifts, other estate provisions) of any amount or percentage of estate to the Keystone Symposia Future of Science Fund. Keystone Society members will be recognized in perpetuity on all Keystone Symposia acknowledgement platforms, including websites, conference books and annual reports.

Those joining The Keystone Society before June 30, 2014 are recognized in perpetuity as Charter Members. Donors always have the option of making their gifts anonymously.

PLATINUM ($50,000+)

American Association for the Advancement of Science (AAAS)BioMed Central LtdCell PressEMBO PressNature Publishing GroupThe Scientist

GOLD ($25,000–$49,999)

Cold Spring Harbor Laboratory PressMary Ann Liebert, Inc. PublishersPLOSS. Karger A.G.The Rockefeller University Press – The Journal of Cell Biology

SILVER ($10,000–$24,999)

FOCIS (Federation of Clinical Immunology Societies)NeuroScientistNewsThe Company of Biologists LtdThe Rockefeller University Press – The Journal of Experimental Medicine

BRONZE ($2,500–$4,999)

British Society for ImmunologyEuropean Journal of ImmunologyGenetic Engineering & Biotechnology NewsThe Journal of Clinical InvestigationThe Journal of RheumatologyTuberculosis (published by Elsevier)

CONTRIBUTING (up to $2,499)

International Society for Experimental Hematology (ISEH)International Society for Stem Cell Research (ISSCR)neurogenetics (published by Springer)Neurology® Neuroimmunology & NeuroinflammationThe Beatson Institute for Cancer Research

The following publishers, societies and other organizations provided in-kind marketing and advertising support that helped publicize the 2015 Keystone Symposia meeting series.

mEdiA PARTNERs

*Indicates a donation on a recurring monthly basis.

Jo VineyDavid and Marcy Woodland

19

ThE ANdy ROBERTsON mEmORiAL FUNd FOR divERsiTy iN LiFE sCiENCE dONORs Dr. Andy Robertson, who passed away unexpectedly in August 2014, was Keystone Symposia’s Chief Scientific Officer from 2005 to 2011. He made a number of critical contributions while with us, including launching Keystone Symposia’s Diversity in Life Science program, the work at Keystone Symposia that moved him most. In tribute to Andy’s legacy and memory, Keystone Symposia inaugurated the Andy Robertson Memorial Fund for Diversity in Life Science. With the generous support of the following donors, Keystone Symposia established an endowed fund to underwrite scholarships for underrepresented trainee scientists.

Patricia AguilarNatalie AhnMicheala AldredDr. Lee-Ann AllenSharilyn AlmodovarStephen AndersonChristopher AtwoodJenna and Scott Bednar-PageAlberto BosqueDawn L. BrasaemleCecily L. BrayCaroline BreitbachAmanda BrownCherié Butts with matching gift from Biogen Idec FoundationJohn CantwellPiero CarninciEsmeralda CasasRichard CatesWalter ChazinValerio ChiurchiùPamela S. DaughertyDr. Edward A. DennisAlexandre DeshiereVishva DixitAnne DurandyRebecca DutchDavid EliezerLee Ellis

Beverly EmersonSharon E. Flanagan and Dale F. FlanaganNicole FrahmMasataka HaradaHelke HillebrandJennifer HondaAndrew HoukBob and Linda HrycajKris HuygenAdam IdicaElizabeth JaffeeShingo KajimuraChristopher Karp and Marsha Wills-Karp with matching gift from the Bill & Melinda Gates FoundationPeter S. KimIgor B. KramnikLawrence LambMark LangAntonio LanzavecchiaJoel LindenEdison T. Liu and Margaret B. LiuMargaret Liu and Robert JohnsonSlobodan MacuraPhyllis McNeilBlandine MonelWalter Moos and Susan MillerTanya Muller and David GarnerRalph Nixon

Helena Nunes-CabaçoTrudy OliverVito PalombellaEric M. ParkerJose Perez-PoloJane L. Peterson and Kenneth J. CremerPeter PreveligeRonald RainesJill ReifschneiderChuck ReynoldsFederica SallustoJanet M. ShawMadeline A. Shea and Marc S. WoldAlan SherHeidi Daetwyler SimpsonGreg SpearGerald SufrinThermo Fisher Scientific Inc.Raul Torres and Roberta PelandaBruno VaslinIan A. WilsonAprilianto Eddy WiriaMarc WoldDavid and Marcy WoodlandBo WuTachi and Leslie YamadaBei Zhang

JoAnne Flynn served as the lead organizer of Keystone Symposia’s January 2015 meeting on Host Response in

Tuberculosis, with co-organizer Willem Hanekom. For the first time, this meeting was held jointly with a conference on Granulomas in Infectious and Non-Infectious Diseases organized by Thomas Wynn, Paul Kaye and Vishva Dixit.

Dr. Flynn is Professor at the University of Pittsburgh School of Medicine. Her research in tuberculosis is focused on immunology, host-pathogen interactions, vaccines, drugs and animal models. She has developed and used the non-human primate as a model for TB over the past 14 years. The image at the left shows a PET/CT scan of a Mycobacterium-infected macaque with lung granulomas identified by purple arrows and involved thoracic lymph nodes identified by yellow arrows. Dr. Flynn’s lab uses these scans for serial tracking of infection.

JOANNE FLYNN, Ph.D., TUBERCULOSIS

Juleen R. Zierath, Ph.D.Chair of the Board, Keystone SymposiaProfessor, Molecular Medicine and Surgery, Karolinska Institutet

Gary J. Nabel, M.D., Ph.D. Secretary of the Board Chair, Scientific Advisory Board, Keystone Symposia Chief Scientific Officer, Research and Development Sanofi

Walter Moos, Ph.D.Treasurer of the Board, Chair, Finance Committee, Keystone SymposiaVice President, Biosciences Division, SRI International

Jane L. Peterson, Ph.D.President and Chief Executive OfficerKeystone Symposia on Molecular and Cellular Biology

David L. Woodland, Ph.D.Chief Scientific OfficerKeystone Symposia on Molecular and Cellular Biology

E. Dale Abel, M.D., Ph.D. Director, F.O.E. Diabetes Research Center Professor of Medicine and Biochemistry University of Iowa Carver College of Medicine

Vishva M. Dixit, M.D. Vice President, Early Discovery Research and Physiological Chemistry Genentech, Inc.

Beverly M. Emerson, Ph.D.Chair, Personnel Committee, Keystone SymposiaProfessor, Regulatory Biology LaboratoryThe Salk Institute

Peter M. Finan, Ph.D.Chair, Audit Committee, Keystone SymposiaVenture Partner, Epidarex CapitalHead of Biology, Karus Therapeutics

Margaret “Peggy” Goodell, Ph.D.Professor and Director, Stem Cells & Regenerative Medicine CenterPediatrics, Baylor College of Medicine

Heidi E. Hamm, Ph.D.Professor, Department of PharmacologyVanderbilt University School of Medicine

Juan Carlos Lopez, Ph.D.Head, Academic Relations and CollaborationsPharmaceutical Research and Early Development Roche

Anne O’Garra, Ph.D., F.R.S., F.Med.Sci.Associate Research DirectorThe Francis Crick Institute, Mill Hill Laboratory

Alan Sher, Ph.D.Chair, Nominating Committee, Keystone SymposiaBethesda, Maryland

Ian A. Wilson, Ph.D., Sc.D., FRSProfessor and Chair, Integrative Structural and Computational BiologyThe Scripps Research Institute

Tadataka Yamada, M.D. Managing Partner, Mountain Field LLCBei B. Zhang, Ph.D. General Manager, Lilly China Research and Development Co. LTD (LCRDC) Vice President, Lilly Research Laboratories, Eli Lilly and Company

EMERITUS BOARD MEMBERS

Ralph A. Bradshaw, Ph.D.Professor Emeritus, Physiology and BiophysicsCollege of Medicine, University of California, IrvineProfessor in Pharmaceutical Chemistry and Deputy Director of Mass Spectrometry Facility, University of California, San Francisco

Edward A. Dennis, Ph.D.Professor, Chemistry, Biochemistry and PharmacologySchool of Medicine, University of California, San Diego

Curtis C. Harris, M.D.Chief, Laboratory of Human CarcinogenesisNCI/National Institutes of Health

Note: All Board and Emeritus Board Members are also members of Keystone Symposia’s Scientific Advisory Board.

Jane L. Peterson, Chief Executive OfficerPamela Daugherty, Chief Financial OfficerDavid Woodland, Chief Scientific OfficerJeannie Dalrymple, Senior Director, Global DevelopmentLinda Hrycaj, Senior Director, Strategic PlanningRick Sherman, Vice President, Development Nick Dua, Director, Digital MediaIrelene Ricks, Director, Diversity in Life Science ProgramsTanya Muller, Director, Information TechnologyYvonne Psaila, Director, Marketing & CommunicationsMary Jo Roal, Director, Human ResourcesHeidi Daetwyler Simpson, Director, Meeting Management David Adamson, On-Site Staff RepresentativeCathy Banks, Web Developer/Systems AnalystCarol Bosserman, On-Site Staff RepresentativeMary Brown, On-Site Staff RepresentativeCaroline Brendel, Executive Administrative AssistantDoug Castle, Web Developer/Systems AnalystLinda Cooper, Abstracts AssistantAshley Connally, Office ManagerChris Dean, IT Support Specialist

Amanda Deem, Assistant Director of DevelopmentHeather Ford, Manager, Attendee ServicesMarcus Fresia, Logistics SpecialistHeather Gerhart, Senior Grant Coordinator/Program AnalystLindsey Heilmann, Conference CoordinatorJenny Hindorff, Program Development CoordinatorBeth Johnson, Administrative & Research Assistant, DevelopmentSarah Lavicka, Assistant Director of DevelopmentJeff Lehman, Scholarship CoordinatorKellie McConnell, Program Implementation AssistantPhyllis McNeil, Attendee Services SpecialistAlexa Morrison, Program Implementation AssociatePauli Novak, Marketing AssistantAllison Ogdon, Associate Director, Program Development & ImplementationAnnie Page, On-Site Staff RepresentativeJulie Roll, On-Site Staff RepresentativeBarbara Schmid-Miller, Marketing Assistant Dawn Shafer, Accounting ClerkKiki Sperr, Scientific Program AnalystKathy Tavares, Program Implementation SupervisorRebecca Wilkerson, Finance Assistant

20

BOARd OF diRECTORs (as of December 31, 2015)

sTAFF (as of December 31, 2015)

Bob Craig served on Keystone Symposia’s Board of Directors for many years and as an Emeritus Board Member since 2008 until his death in

2015. As founder of The Keystone Center, a nonprofit “think tank” now called Keystone Policy Center, he was instrumental in finding a home for Keystone Symposia within the Center after it left the University of California, Los Angeles in 1990. Although Keystone Symposia later separated from The Keystone Center to become an independent nonprofit organization in 1996, he remained a loyal supporter, staying on the Board and offering sage and steady advice as Keystone Symposia expanded. It was great to have a “local” on the Board who could help Keystone Symposia establish roots in the Summit County, Colorado community.

Before founding The Keystone Center, Bob was one of the first leaders of the Aspen Institute and co-founder of the Aspen Center for Physics. He was also a mountaineer who scaled Everest and K2. He was a true Renaissance and “ideas” man, with remarkably diverse interests and a strong belief in bringing divergent fields together. In 1991, he wrote of Keystone Symposia’s scientist attendees: “I was pleased as well to observe that these same hard working souls (who never seem to get any sleep) were also just as dedicated to skiing hard and tramping through the mountains, and the Symposia confirmed my commitment to William Blake’s observation that ‘great things happen when men and mountains meet.’ ”

In Memoriam: Board Member Robert Craig (1921–2015)

We will all miss our original Emeritus Trustee Bob Craig, who played such a key role in the evolution of the Keystone Symposia and was such a wonderful role model for us all.– Emeritus Board Member Ed Dennis

He was a mountain of a man and a great inspiration to us all.– Chair of the Board Juleen Zierath

“

“

”

”If at a conference in Keystone, Colorado, be sure to take a run in his honor on “Oh Bob,” the ski run named after him!

21

Black-and-white photos above courtesy of Keystone Policy Center.

Luciano Adorini, M.D. Chief Scientific Officer, Preclinical Research Intercept Pharmaceuticals, Inc.

James E. Audia, Ph.D. Chief Scientific Officer Constellation Pharmaceuticals

Jacques F. Banchereau, Ph.D. Professor and Director of Immunological Sciences The Jackson Laboratory for Genomic Medicine

J. Carl Barrett, Ph.D. Vice President, Translational Science Oncology Innovative Medicines AstraZeneca

Dominic P. Behan, Ph.D., D.Sc. Executive Vice President and Chief Scientific Officer Arena Pharmaceuticals, Inc.

Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer Dynavax Technologies

Rodrigo Corrêa-Oliveira, Ph.D. Senior Researcher Laboratório de Imunologia Celular e Molecular FIOCRUZ Minas

Russell A. DeBose-Boyd, Ph.D. Professor Molecular Genetics University of Texas Southwestern Medical Center

Martin P. Edwards, Ph.D. Vice President, Cancer Chemistry Pfizer La Jolla

Curt R. Freed, M.D. Professor and Head Division of Clinical Pharmacology and Toxicology University of Colorado, Denver

Adolfo García-Sastre, Ph.D. Professor, Microbiology Mount Sinai School of Medicine

Tariq Ghayur, Ph.D. Senior Research Fellow Biologics AbbVie

Geoffrey S. Ginsburg, M.D., Ph.D. Director, Center for Applied Genomics and Precision Medicine Center for Applied Genomics and Center for Personalized and Precision Medicine Duke University

Margaret A. Goodell, Ph.D. Professor, Pediatrics, Hematology/Oncology Director, STaR Center Center for Cell and Gene Therapy Baylor College of Medicine

Philip D. Gregory, Ph.D. Chief Scientific Officer Research Sangamo BioSciences, Inc

Diane E. Griffin, M.D., Ph.D. Professor and Chair Molecular Microbiology and Immunology Johns Hopkins Bloomberg School of Public Health

Austin Gurney, Ph.D. Senior Vice President, Molecular and Cellular Biology OncoMed Pharmaceuticals, Inc.

Jacqueline E. Heard, Ph.D. CEO Two Blades Foundation

Sharath S. Hegde, Ph.D.Vice President, Department of PharmacologyTheravance, Inc.

Kim A. Heidenreich, Ph.D. Professor, Department of Pharmacology University of Colorado Denver (UCHSC)

Matthew F. Heil, Ph.D. Chief Scientific Officer Research and Development Curemark LLC

Linda Slanec Higgins, Ph.D. Vice President, Biology Gilead Sciences, Inc.

Sean Hill, Ph.D. Professor, Brain and Mind Institute École Polytechnique Fédérale de Lausanne (EPFL)

Reid M. Huber, Ph.D. Executive Vice President, Chief Scientific Officer Discovery Biology Incyte Corporation

Tony Hunter, Ph.D. Professor, Molecular Biology and Cellular Biology Lab The Salk Institute

Allan R. Jones, Ph.D. Chief Executive Officer Allen Institute for Brain Science

J. Keith Joung, M.D., Ph.D. The Jim and Ann Orr MGH Research Scholar Associate Chief of Pathology for Research Molecular Pathology Unit Massachusetts General Hospital Professor of Pathology, Harvard Medical School

Christopher L. Karp, M.D. Deputy Director, Vaccines and Host-Pathogen Biology Global Health Discovery and Translational Sciences Bill & Melinda Gates Foundation

Laura L. Kiessling, Ph.D. Hilldale Professor of Chemistry Laurens Anderson Professor of Biochemistry Department of Chemistry and Biochemistry University of Wisconsin–Madison

Jacqueline Kirchner, Ph.D. Executive Director, Research Inflammation Amgen

Karla Kirkegaard, Ph.D. Violetta Horton Professor Genetics, Microbiology and Immunology Stanford University School of Medicine

Gerhard Koenig, Ph.D. Senior Vice President, Research Chief Scientific Officer FORUM Pharmaceuticals, Inc.

Martin Kussmann, Ph.D. Head of Molecular Biomarkers Nestlé Institute of Health Sciences

Tony K. T. Lam, Ph.D. Professor and J.K. McIvor Endowed Chair in Diabetes Research Canada Research Chair in Obesity Associate Director, Banting and Best Diabetes Centre Advanced Diagnostics and Metabolism Toronto General Research Institute

John M. Lambert, Ph.D. Executive Vice President and Distinguished Research Fellow Research ImmunoGen, Inc

Jan E. Leach, Ph.D. University Distinguished Professor Bioagricultural Sciences Colorado State University

Hyam I. Levitsky, M.D. Head, Cancer Immunotherapy Experimental Medicine Roche Innovation Center Zurich

Dangsheng Li, Ph.D. Deputy Editor-in-Chief Cell Research Shanghai Institutes for Biological Sciences Chinese Academy of Sciences

Timothy B. Lowinger, Ph.D. Chief Scientific Officer Mersana Therapeutics

Paolo G.V. Martini, Ph.D. Senior Director Drug Discovery and Translational Research Shire Human Genetic Therapies

Tetsuyuki Maruyama, Ph.D. Corporate Officer, General Manager, Head Pharmaceutical Research Division Takeda Pharmaceutical Company Ltd.

sCiENTiFiC AdvisORy BOARd (as of June 30, 2015)

22

Note: All Board and Emeritus Board Members listed on page 20 are also members of Keystone Symposia’s Scientific Advisory Board.

Lamine Mbow, Ph.D. Director, Immunology and Inflammation Boehringer Ingelheim

M. Juliana McElrath, M.D., Ph.D. Senior Vice President, Director and Member Vaccine and Infectious Disease Division Fred Hutchinson Cancer Research Center

Elizabeth M. McNally, M.D., Ph.D. Director, Center for Genetic Medicine Northwestern University Feinberg School of Medicine

Juanita L. Merchant, M.D., Ph.D. Professor, Internal Medicine and Molecular and Integrative Physiology University of Michigan

Tara Mirzadegan, Ph.D. Senior Director, CREATe Janssen R&D: Pharmaceutical Companies of Johnson & Johnson

Craig Monell, Ph.D. Vice President Business Operations/R&D BioLegend, Inc.

Dominik Mumberg, Ph.D. Director, Cell Cycle and Survival Signaling Research Global Drug Discovery Bayer HealthCare

Andrew Murphy, Ph.D. Senior Vice President of Research Regeneron Pharmaceuticals, Inc.

Leon O. Murphy, Ph.D. Director Novartis Pharmaceuticals

Steven G. Nadler, Ph.D. Group Director Translational Research Immuno-Sciences Biology Drug Discovery Bristol-Myers Squibb Company

Vito J. Palombella, Ph.D. Chief Scientific Officer Infinity Pharmaceuticals, Inc.

Eric M. Parker, Ph.D. Senior Director and Neuroscience Site Lead Neuroscience and Ophthalmology Merck Research Laboratories

Paul W.H.I. Parren, Ph.D. Senior Vice President and Scientific Director Genmab B.V.

Roberto D. Polakiewicz, Ph.D. Chief Scientific Officer Cell Signaling Technology, Inc.

Mark Powers, Ph.D. Senior Director, Research & Development Primary and Stem Cell Systems Life Technologies Corporation

Bali Pulendran, Ph.D. Professor Emory Vaccine Center Emory University

Ronald T. Raines, Ph.D. Professor Departments of Biochemistry and Chemistry University of Wisconsin–Madison

Cristina M. Rondinone, Ph.D. Vice President, Research and Development Head, Cardiovascular and Metabolic Diseases MedImmune

Nadia A. Rosenthal, Ph.D. Director, Australian Regenerative Medicine Institute Scientific Head, EMBL Australia Monash University

Andrej Sali, Ph.D. Professor, Bioengineering and Therapeutic Sciences University of California, San Francisco

Alejandro Sánchez-Alvarado, Ph.D. Investigator HHMI/Stowers Institute for Medical Research

Terrence J. Sejnowski, Ph.D. Director, Computational Neurobiology Laboratory The Salk Institute

Ali Shilatifard, Ph.D. Robert Francis Furchgott Professor Chairman, Department of Biochemistry and Molecular Genetics Northwestern University Feinberg School of Medicine

Frank J. Slack, Ph.D. Director, Institute for RNA Medicine Pathology BIDMC Cancer Center/Harvard Medical School

Hans Ulrich “Uli” Stilz, Ph.D. Vice President R&D Academic Partnerships Novo Nordisk A/S

Lynda Maria Stuart, M.D., Ph.D. Senior Program Officer Global Health, Discovery & Translational Sciences Bill & Melinda Gates Foundation

Eric E. Swayze, Ph.D. Vice President, Medicinal Chemistry Ionis Pharmaceuticals, Inc.

Mathias Uhlén, Ph.D. Professor, School of Biotechnology KTH Royal Institute of Technology

Joanne L. Viney, Ph.D. Vice President, Immunology Research Biogen

Michael J.O. Wakelam, Ph.D. Institute Director The Babraham Institute

Yibin Wang, Ph.D. Professor, Anesthesiology, Physiology and Medicine University of California, Los Angeles David Geffen School of Medicine

Andrew B. Ward, Ph.D. Assistant Professor Integrative Structural and Computational Biology The Scripps Research Institute

Markus Warmuth, M.D. President and Chief Executive Officer H3 Biomedicine Inc.

Kenneth F. Wertman, Ph.D. Scientific Director, Tucson Associate Vice President, Discovery Research Chemical Analytical Sciences Sanofi US

Keith M. Wilcoxen, Ph.D. Senior Director Scientific Research and Development TESARO, Inc.

Peter J. Worland, Ph.D. Vice President, Integrative Research Development Executive Research Celgene Corporation

Joseph C. Wu, M.D., Ph.D. Professor and Director Stanford Cardiovascular Institute Medicine and Radiology Stanford University School of Medicine

Xuebiao Yao, Ph.D. Professor and Head Cellular Dynamics University of Science & Technology of China

Michael J. Zigmond, Ph.D. Professor of Neurology, Psychiatry and Behavioral and Community Health Sciences Neurology University of Pittsburgh

plus representatives to be announced from:Monsanto Company NeoStem, Inc.Sarepta TherapeuticsVertex Pharmaceuticals Incorporated

Note: All Board and Emeritus Board Members listed on page 20 are also members of Keystone Symposia’s Scientific Advisory Board.

PO Box 1630 | 160 US Highway 6, Suite 200Silverthorne, Colorado 80498 | USA

1.970.262.1230 | 1.800.253.0685 www.keystonesymposia.org